BTIG keeps Buy ratings on Avalo and HubSpot but moves their price targets in opposite directions
BTIG maintained Buy on Avalo Therapeutics while cutting its target to $10, and kept Buy on HubSpot while raising its target to $300. Source: Dow Jones Newswires.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Investment firm BTIG has maintained its Buy rating on Avalo Therapeutics but reduced its price target on the stock to $10 from $58. The update, based on Benzinga ratings data, was reported by Dow Jones Newswires.
For HubSpot, BTIG also kept its Buy rating, yet lifted its price target to $300 from $250. The change appeared in the same batch of analyst rating actions.
why it matters
Entries like these are routine analyst updates and usually affect only the individual stocks involved. The Avalo target cut is far larger than the HubSpot increase, so the two moves point in opposite directions. Investors typically weigh such changes against company results and broader sector trends.
tags
instruments
sources
- Avalo Therapeutics Is Maintained at Buy by BTIG — Dow Jones Newswires, 23 October 2026 at 09:52 UTC
- HubSpot Is Maintained at Buy by BTIG — Dow Jones Newswires, 23 October 2026 at 10:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗